Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
NCT05989347
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Hyperinsulinism
HER2-negative Breast Cancer
Interventions
DRUG:
Dapagliflozin 10mg
Sponsor
Yale University